Calponin h1-gene therapy using Tat-peptide vector against peritoneal dissemination of ovarian cancer
Project/Area Number |
24592520
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Obstetrics and gynecology
|
Research Institution | Kagoshima University (2014) Kyushu University (2012-2013) |
Principal Investigator |
KOBAYASHI Hiroaki 鹿児島大学, 医歯(薬)学総合研究科, 准教授 (70260700)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
Keywords | カルポニンh1 / アクチン / 細胞骨格蛋白質 / 卵巣癌 / 癌性腹膜炎 / 分子標的治療 / Tatペプチド / 膜透過性ペプチド / カルポニンリピート構造 / 卵巣がん / Cell-penetrating peptide / 腹膜播種 |
Outline of Final Research Achievements |
Objectives: Actin binding protein calponin h1 (CNh1) stabilizes cytoskeletal actin. We tried to identify the responsibility site in actin stabilization which can be a molecular target for ovarian cancer therapy. Methods: The full length or several mutant form of CNh1 were constructed and introduced into ovarian cancer cell lines. Immunocytochemistry was performed to evaluate the localization of transfected CNh1 and the level of actin polymerization. The growth, migration and invasion ability of transfected cells were also measured. Results: The ratio of actin polymerization was revealed as follows: 73% in CNh1 full length transfection; 66% in calponin repeat structure (CNR1); 36% in mock transfection. The cell morphology changed depending on the actin polymerization. The growth, migration and invasion ability were significantly suppressed in both CNh1 full length and CNR1 introduced cells. Conclusion: CNR1 was suggested to become a molecular target for ovarian cancer therapy.
|
Report
(4 results)
Research Products
(18 results)
-
-
[Journal Article] Uterine myxoid leiomyosarcoma with tumor embolism extending into the right atrium2015
Author(s)
Hiromi Imai, Hiroshi Yagi, Kaoru Okugawa, Hironori Kenjo, Tatsuhiro Ohgami, Yoshiaki Kawano, Eisuke Kaneki, Akimasa Ichinoe, Kazuo Asanoma, Hideaki Yahata, Kenzo Sonoda, Hiroaki Kobayashi, Tsunehisa Kaku, Kiyoko Kato
-
Journal Title
Case Reports in Obstetrics and Gynecology
Volume: 2015
Pages: 316262-316262
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour2015
Author(s)
Satoh T, Aoki Y, Kasamatsu T, Ochiai K, Takano M, Watanabe Y, Kikkawa F, Takeshima N, Hatae M, Yokota H, Saito T, Yaegashi N, Kobayashi H, Baba T, Kodama S, Saito T
-
Journal Title
Eur J Cancer
Volume: 51
Issue: 3
Pages: 340-51
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
[Journal Article] Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102).2013
Author(s)
Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Nakanishi T, Yasugi T, Yaegashi N, Yokota H, Kodama S , Mizunoe T, Hiura M, Kasamatsu T, Shibata T, Kamura T
-
Journal Title
Br J Cancer.
Volume: 108(10)
Issue: 10
Pages: 1957-1963
DOI
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Inhibition of AHR transcription by NF1C is affected by a single nucleotide polymorphism, and is involved in suppression of human uterine endometrial cancer2013
Author(s)
Li D, Takao T, Tsunematsu R, Morokuma S, Fukushima K, Kobayashi H, Saito T, Furue M, Wake N, Asanoma K
-
Journal Title
Related Report
Peer Reviewed
-
-
-
-